We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
依达拉奉联合纳美芬对急性重型颅脑损伤患者血清神经细胞因子和炎性 因子的影响
- Authors
孙尊鹏; 刘荣明; 葛卫星; 严金霞; 路玉宇
- Abstract
Objective: To investigate the effect of edaravone combined with nalmefene in serum nerve cell factors and inflammatory factors in patients with acute severe craniocerebral injury. Methods: 80 patients with acute severe brain injury who were received in our hospital from January 2015 to December 2017 were selected, and they were randomly divided into control group(n=40) and observation group (n=40). The patients in the control group were received routine comprehensive treatment after admission, on this basis, the observation group were given edaravone combined with nalmefene treatment. The levels of serum nerve cell factors, inflammatory factors, Glasgow Coma Scale (GCS), acute physiology and chronic health status II (APACHE II) score were compared between the two groups, the intracranial pressure, brain edema and adverse reaction were observed in the two groups. Results: The levels of serum β-endorphin, S100βprotein and neuron specific enolase (NSE) in the observation group at 1d and 1 week after treatment were lower than those before treatment and in the control group (P<0.05). The levels of serum high sensitivity C reactive protein (hs-CRP), tumor necrosis factor-α(TNF-α), interleukin-8(IL-8) of patients in two groups at 1 week after treatment were lower than before treatment, and the observation group was lower than the control group (P<0.05). The proportion of intracranial pressure <15 mmHg and the proportion of mild cerebral edema at 1 week after treatment in the observation group were higher than that of the control group (P<0.05), proportion of intracranial pressure ≥ 20 mmHg and the proportion of severe brain edema proportion was lower than that of the control group (P<0.05). The score of GCS in the two groups was higher than that before treatment at 1 week after treatment, and the score of APACHE II was lower than that before treatment(P<0.05). The score of GCS in the observation group was higher than that of the control group at 1 week after treatment, and the score of APACHE II was lower than that of the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Concluvion: Edaravone combined with nalmefene can significantly improve nerve cell factors and inflammatory factors levels of patients with acute severe craniocerebral injury, and it promotes the reduction of intracranial pressure and the absorption of brain edema, which is beneficial to the prognosis of the patients and has good safety.
- Subjects
EDEMA; GLASGOW Coma Scale; INTRACRANIAL pressure; CRANIOCEREBRAL injuries; NEURONS; CEREBRAL edema; EDARAVONE
- Publication
Progress in Modern Biomedicine, 2018, Vol 18, Issue 23, p4522
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2018.23.029